Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <i>BRCA</i> -Mutant Ovarian Cancer Models
Hyoung Kim(University of Pennsylvania), Fiona Simpkins(The Wistar Institute)
Cited by 292
Related Papers
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers
|JCI Insight|2017|71
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
|iScience|2024|11